Alagille Syndrome

Odevixibat shows promise in alleviating symptoms of Alagille syndrome: Phase 3 ASSERT study results

The phase 3 ASSERT study has demonstrated the effectiveness and safety of odevixibat in treating Alagille syndrome (ALGS), according to a poster presented at The Liver Meeting 2023. Patients who responded positively to odevixibat showed significant reductions in bile acids, improved pruritus symptoms, enhanced sleep parameters, and better quality of...